FDA Classifies Cardiac Allograft Gene Expression Profiling Test Systems as Class II Devices with Special Controls

Summary

The FDA has classified cardiac allograft gene expression profiling test systems into Class II, requiring special controls to ensure safety and effectiveness. The agency has published a guidance document outlining these controls, which is available on the FDA website.